Lumos Pharma, Inc. (NASDAQ:LUMO – Get Free Report) was the target of a large decrease in short interest during the month of October. As of October 31st, there was short interest totalling 240,800 shares, a decrease of 6.8% from the October 15th total of 258,300 shares. Currently, 5.2% of the shares of the stock are short sold. Based on an average daily volume of 116,600 shares, the short-interest ratio is currently 2.1 days.
Hedge Funds Weigh In On Lumos Pharma
A number of institutional investors have recently modified their holdings of the stock. Jefferies Financial Group Inc. purchased a new position in Lumos Pharma during the fourth quarter valued at approximately $436,000. Greenwich Wealth Management LLC increased its holdings in Lumos Pharma by 55.8% during the third quarter. Greenwich Wealth Management LLC now owns 76,341 shares of the company’s stock valued at $252,000 after buying an additional 27,339 shares during the period. Geode Capital Management LLC increased its holdings in Lumos Pharma by 58.5% during the second quarter. Geode Capital Management LLC now owns 54,279 shares of the company’s stock valued at $179,000 after buying an additional 20,023 shares during the period. Shay Capital LLC purchased a new position in Lumos Pharma in the fourth quarter worth $180,000. Finally, Private Advisor Group LLC purchased a new position in Lumos Pharma in the first quarter worth $263,000. 35.23% of the stock is owned by hedge funds and other institutional investors.
Lumos Pharma Stock Up 2.0 %
Shares of NASDAQ:LUMO opened at $3.06 on Friday. The firm’s 50 day simple moving average is $3.54 and its 200-day simple moving average is $3.44. Lumos Pharma has a one year low of $2.63 and a one year high of $5.53.
Wall Street Analyst Weigh In
Lumos Pharma Company Profile
Lumos Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its primary product candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 3 clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders.
- Five stocks we like better than Lumos Pharma
- How to Find Cloud Software Company Stocks to Trade and Invest
- MarketBeat Week in Review – 11/13 – 11/17
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- 3 large caps with red hot RSIs with upside
- How to Invest in Mining Stocks
- Johnson Controls International: Nothing but upside for investors
Receive News & Ratings for Lumos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lumos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.